NCT02180165View on ClinicalTrials.gov

Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)

PHASE3CompletedINTERVENTIONAL

Enrollment

116

Participants

Timeline

Start Date

July 29, 2014

Primary Completion Date

January 24, 2018

Study Completion Date

January 24, 2018

Conditions

Aspergillosis

Interventions

DRUG

Posaconazole

300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days

DRUG

Voriconazole

300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02180165 - Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) | Biotech Hunter | Biotech Hunter